RWM
BBIO icon

Raffa Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

Raffa Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298 Buy
4
+2
+100% +$140 ﹤0.01% 1222
2026
Q1 		$149 Buy
+2
New +$145 ﹤0.01% 1224

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Raffa Wealth Management's BBIO Position: Q2 2026 in Review

Raffa Wealth Management increased its BridgeBio Pharma (BBIO) stake by 100% in Q2 2026, buying an estimated $140 and bringing the position to 4 shares worth $298. The position accounts for ﹤0.01% of the portfolio, ranked #1222.

Raffa Wealth Management first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 439 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Raffa Wealth Management held 4 shares of BridgeBio Pharma worth $298 as of Q2 2026.
  • Raffa Wealth Management bought 2 BridgeBio Pharma shares in Q2 2026, an estimated $140.
  • BridgeBio Pharma made up ﹤0.01% of Raffa Wealth Management's portfolio in Q2 2026, its #1222 holding.
  • Raffa Wealth Management first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • 439 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Raffa Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.